V-9302

Name: V-9302
Brand: MedChemExpress
SKU: HY-112683
Rating: 5.0 (34 reviews)

Cat. No.: HY-112683 Purity: 99.46%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀=9.6 μM) in HEK-293 cells.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 1855871-76-9

사이즈	재고	수량

무료 샘플 (0.1 - 0.2 mg)	지금 신청하기
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 34 publication(s) in Google Scholar

Other Forms of V-9302:

V-9302 hydrochloride In-stock

34 Publications Citing Use of MCE V-9302

Cell Imaging/Staining

In Vivo Efficacy Study

Others

IHC

Bio/Physico-chemical Assay

: V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 10:e07057. [Abstract]; V-9302 (50 μM, 35 min) suppressed the bioluminescent intensity of HCT116‐luc cells.

: V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 16:e2411479. [Abstract]; V9302 (s.c., 30 mg kg⁻¹, 20 days) in combination with LL202 (s.c., 30 mg kg⁻¹, 20 days) inhibited tumor growth in the H1975OR xenograft model.

: V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 10:e07057. [Abstract]; V-9302 (25 or 50 μM, 35 min) lowered the total photon flux induced by BL568 or AA201 in HCT116‐luc cells.

: V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 16:e2411479. [Abstract]; V9302 (s.c., 30 mg kg⁻¹, 20 days) in combination with LL202 (s.c., 30 mg kg⁻¹, 20 days) increased γH2AX expression level and the number of TUNEL‑positive cells in the H1975OR xenograft model.

: V-9302 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 10:e07057. [Abstract]; V-9302 (25 μM, 70 min) reduced intracellular AA201 levels in all three cell lines.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ASCT Isoform Specific Products:

View All Isoforms

ASCT2

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target

ASCT2

Cellular Effect

Cell Line	Type	Value	Description	References
C6	IC₅₀	9 3 Compound: 17	Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]
C6	IC₅₀	9 3 Compound: 17	Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]
HEK293	IC₅₀	9.6 3 Compound: 17	Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]
HEK293	IC₅₀	9.6 3 Compound: 17	Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]
A549	IC₅₀	20.46 3 Compound: V9302	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 38217503]
C6	IC₅₀	9 3 Compound: 17	Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in rat C6 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]
HEK293	IC₅₀	9.6 3 Compound: 17	Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting Inhibition of ASCT2-mediated glutamine transport in human HEK293 cells using [3H]-glutamine after 15 mins by scintillation counting	[PMID: 26750251]

In Vitro

V-9302 inhibits ASCT2-mediated glutamine uptake in human cells in a concentration-dependent fashion and exhibits a 100-fold improvement in potency over gamma-L-glutamyl-p-nitroanilide^[1].
Pharmacological blockade of ASCT2 with V-9302 results in attenuated cancer cell growth and proliferation, increases cell death, and increases oxidative stress^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

V-9302 (75 mg/kg; i.p.; daily fo 21 days) prevents tumor growth in both HCT-116 and HT29 xenograft models^[1].
The combination of CB-839 and V-9302 (30 mg/kg; i.p.; SNU398 and MHCC97H cells were grown as tumor xenografts in BALB/c nude mice; for 20 or 15 d, respectively) elicits a strong growth inhibition in both SNU398 and MHCC97H xenograft models, while single-drug treatment showed modest anti-tumor effects^[2].
V-9302 (50 mg/kg ; i.p.; daily for 5 days) displays markedly reduced tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old, female athymic nude mice (bearing HCT-116 (KRAS G13D) or HT29 (BRAF V600E) cell-line)^[1]
Dosage:	75 mg/kg
Administration:	Intraperitoneally; daily fo 21 days
Result:	Prevented tumor growth.

분자량

538.68

화학식

C₃₄H₃₈N₂O₄

CAS No.

1855871-76-9

Appearance

Solid

Color

White to yellow

SMILES

O=C(O)[C@@H](N)CCN(CC1=CC=CC=C1OCC2=CC=CC(C)=C2)CC3=CC=CC=C3OCC4=CC=CC(C)=C4

선적

Room temperature in continental US; may vary elsewhere.

보관

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

용액&용해도

In Vitro:

DMSO : 25 mg/mL (46.41 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8564 mL	9.2819 mL	18.5639 mL
5 mM	0.3713 mL	1.8564 mL	3.7128 mL
10 mM	0.1856 mL	0.9282 mL	1.8564 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1 mg/mL (1.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 99.46%

Select Batch:

Data Sheet (281 KB) SDS (252 KB)

COA (257 KB) HNMR (279 KB) RP-HPLC (256 KB) MS (205 KB)

Handling Instructions (2659 KB)

References

[1]. Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202. [Content Brief]

[2]. Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5. [Content Brief]

[3]. Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8564 mL	9.2819 mL	18.5639 mL	46.4097 mL
	5 mM	0.3713 mL	1.8564 mL	3.7128 mL	9.2819 mL
	10 mM	0.1856 mL	0.9282 mL	1.8564 mL	4.6410 mL
	15 mM	0.1238 mL	0.6188 mL	1.2376 mL	3.0940 mL
	20 mM	0.0928 mL	0.4641 mL	0.9282 mL	2.3205 mL
	25 mM	0.0743 mL	0.3713 mL	0.7426 mL	1.8564 mL
	30 mM	0.0619 mL	0.3094 mL	0.6188 mL	1.5470 mL
	40 mM	0.0464 mL	0.2320 mL	0.4641 mL	1.1602 mL

V-9302 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

최근 본 상품:

상품명

Requested Quantity *

고객명 *

호칭

메일주소 *

전화번호 *

Department

회사명 *

City

도

Country or Region *

비고

상품명

Lot #

고객명 *

메일주소 *

전화번호

Department *

회사명 *

Country or Region *

비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

V-9302

고객리뷰

Other Forms of V-9302:

V-9302 Related Antibodies

34 Publications Citing Use of MCE V-9302

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ASCT Isoform Specific Products:

Biological Activity

순도&문서

References

고객리뷰

V-9302 Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

V-9302 Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report